[Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
Ada R ArtemenkoV G AbramovZ N KonovalovaA N KorenkoD A KrasavinaA L KurenkovNina V LatyshevaM V NaprienkoO R OrlovaElena FilatovaV S ShevchenkoP N YakovlevaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
The results demonstrate that the first Russian botulinum toxin type A (Relatox) is an effective prophylactic treatment for CM in adult patients. Relatox led to significant improvements from baseline in multiple measures of headache symptoms, headache-related disability and quality of life. For the first time, a comparative analysis of two botulinum toxin type A products in parallel groups showed no less (not inferior) efficacy and safety of Relatox relative to Botox in the treatment of CM in adults.